QuantiFERON-TB Gold Plus与其他潜伏结核感染检测诊断性能比较:系统综述与Meta分析
该系统综述与Meta分析比较了QFT-Plus与QFT-GIT及其他潜伏结核感染检测的灵敏度、特异度、重复性和预测能力,检索2013年1月至2020年5月MEDLINE等数据库。结果显示QFT-Plus与QFT-GIT诊断性能相似,灵敏度差异无统计学意义,两者一致性高(kappa 0.83),但重复性均较差,且缺乏免疫抑制人群和儿童数据及预测能力研究。
要点
- QFT-Plus与QFT-GIT诊断性能相似,灵敏度差异无统计学意义。
- 两试验一致性高( pooled kappa 0.83),但重复性均较差。
- 缺乏免疫抑制人群、儿童及预测能力的研究数据。
核心结论
- QFT-Plus的诊断性能与QFT-GIT非常相似。
- 需进一步研究评估QFT-Plus在免疫抑制患者和年幼儿童中的灵敏度,才能判断新版本是否具有优势。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Web of Science和Cochrane系统综述数据库2013年1月至2020年5月。
- 纳入比较QFT-Plus与至少一种其他LTBI检测的研究。
- 从活动性结核患者研究估计灵敏度,从低LTBI风险健康个体研究估计特异度。
- 三名独立评价者评估 eligibility、提取数据并评估偏倚风险。
主要发现
- 与QFT-GIT相比,QFT-Plus在活动性结核患者中的灵敏度高1.3%(95%CI -0.3%至2.9%)。
- 在2项极低LTBI概率患者研究中,QFT-Plus特异度低0.9%(95%CI -2.4%至0.6%)。
- 上述差异均无统计学意义。
- QFT-Plus与QFT-GIT一致性高,合并Cohen kappa为0.83(95%CI 0.79至0.88)。
- QFT-GIT和QFT-Plus的重复性均较差。
关键数值与推荐
- 灵敏度估计基于活动性结核患者研究,所有参与者年龄≥15岁,仅6人为HIV感染者。
- 特异度估计基于低LTBI风险健康个体研究。
- 未发现评估预测能力的研究。
临床怎么用
- QFT-Plus可作为QFT-GIT的替代选择,两者诊断性能相似。
- 在免疫抑制患者和年幼儿童中应用QFT-Plus需谨慎,因证据有限。
- 重复性较差提示需结合临床综合判断,不应仅依赖单次检测结果。
局限性
- 灵敏度估计的研究人群年龄≥15岁,仅6人为HIV感染者,免疫抑制人群数据缺乏。
- 缺乏年幼儿童数据。
- 未发现评估预测能力的研究。
- QFT-GIT和QFT-Plus重复性均较差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a review to compare the sensitivity, specificity, reproducibility, and predictive ability of QuantiFERON-TB Gold Plus (QFT-Plus) with that of QuantiFERON-TB Gold In-Tube (QFT-GIT; QIAGEN, Hilden, Germany) and other latent tuberculosis infection (LTBI) tests. METHODS: We searched MEDLINE, Embase, Web of Science, and the Cochrane Database of Systematic Reviews from January 2013 through May 2020. We included studies comparing QFT-Plus with at least one other LTBI test. We estimated sensitivity from studies of patients with active tuberculosis, and specificity from studies of healthy individuals with low risk of LTBI. Three independent reviewers evaluated eligibility, extracted data, and assessed risk of bias. RESULTS: Compared with QFT-GIT, the sensitivity of QFT-Plus in patients with active TB was 1.3% higher (95% confidence interval [CI], -0.3% to 2.9%); in 2 studies of patients with very low probability of LTBI, the specificity was 0.9% lower (95% CI, -2.4% to 0.6%). These differences were not statistically significant. The agreement between QFT-Plus and QFT-GIT was high, with a pooled Cohen's kappa statistic of 0.83 (95% CI, 0.79 to 0.88). The reproducibility of QFT-GIT and QFT-Plus was similarly poor. All participants in the studies to estimate sensitivity were aged ≥15 years, and only 6 were people living with human immunodeficiency virus. We found no studies to assess predictive ability. CONCLUSIONS: QFT-Plus has diagnostic performance that is very similar to that of QFT-GIT. Further studies are needed to assess the sensitivity of QFT-Plus in immunocompromised patients and younger children before concluding if this new version offers advantages.
引用
- Oh CE, Ortiz-Brizuela E, Bastos ML, et al. Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2021. PMID: 33289038. doi:10.1093/cid/ciaa1822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。